Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...
After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...
The Biden administration on Tuesday proposed that weight-loss drugs be paid for by Medicaid and Medicare, potentially making ...
Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...
High-yielding stocks can be due for cuts to their payouts if a company's underlying financials aren't strong enough to ...
Eli Lilly’s crop of new products propelled the ... a rise of 31% that came despite pricing pressure in the US and competition from Novo Nordisk’s rival once-weekly injectable GLP-1 agonist ...
Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the ...